{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:50:16Z","timestamp":1793710216592,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.joca.2023.08.010","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T11:58:38Z","timestamp":1693310318000},"page":"1612-1626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab"],"prefix":"10.1016","volume":"31","author":[{"given":"John A.","family":"Carrino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"McAlindon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom J.","family":"Schnitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-8266","authenticated-orcid":false,"given":"Ali","family":"Guermazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc C.","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Burr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fountaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn C.","family":"Pixton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8739-0544","authenticated-orcid":false,"given":"Lars","family":"Viktrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine R.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joca.2023.08.010_bib1","first-page":"373","article-title":"Anti-nerve growth factor in pain management: current evidence","volume":"9","author":"Chang","year":"2016","journal-title":"J Pain Res"},{"key":"10.1016\/j.joca.2023.08.010_bib2","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.joca.2014.10.005","article-title":"Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies","volume":"23","author":"Hochberg","year":"2015","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.joca.2023.08.010_bib3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.39492","article-title":"When is osteonecrosis not osteonecrosis?: adjudication of reported serious adverse joint events in the tanezumab clinical development program","volume":"68","author":"Hochberg","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.joca.2023.08.010_bib4","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/art.41674","article-title":"Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial","volume":"73","author":"Hochberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.joca.2023.08.010_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2019.8044","article-title":"Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial","volume":"322","author":"Schnitzer","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.joca.2023.08.010_bib6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/annrheumdis-2019-216296","article-title":"Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period","volume":"79","author":"Berenbaum","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2023.08.010_bib7","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1097\/j.pain.0000000000001625","article-title":"Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety","volume":"160","author":"Schmelz","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.joca.2023.08.010_bib8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3389\/fphar.2020.00817","article-title":"The efficacy of nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: a meta-analysis","volume":"11","author":"Yang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.joca.2023.08.010_bib9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.semarthrit.2017.05.008","article-title":"Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessment","volume":"47","author":"Roemer","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.joca.2023.08.010_bib10","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.joca.2014.09.015","article-title":"Imaging atlas for eligibility and on-study safety of potential knee adverse events in anti-NGF studies (Part 1)","volume":"23","author":"Roemer","year":"2015","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.joca.2023.08.010_bib11","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.joca.2014.09.014","article-title":"Imaging atlas for eligibility and on-study safety of potential hip adverse events in anti-NGF studies (Part 2)","volume":"23","author":"Roemer","year":"2015","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.joca.2023.08.010_bib12","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.joca.2014.09.018","article-title":"Imaging atlas for eligibility and on-study safety of potential shoulder adverse events in anti-NGF studies (Part 3)","volume":"23","author":"Roemer","year":"2015","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.joca.2023.08.010_bib13","unstructured":"Guermazi A, Roemer FW, Kompel AJ, Diaz L, Crema MD, Pixton G, et al. Centralized, single-read, radiographic assessment of patient eligibility in three phase III trials of tanezumab for osteoarthritis: role of reader training, calibration and consensus sessions. ePoster presentation. American College of Radiology Annual Meeting and Chapter Leadership Conference; 2021. Virtual: May 15-19, 2021."},{"key":"10.1016\/j.joca.2023.08.010_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ostima.2022.100082","article-title":"Inter-reader consistency and exclusionary findings during radiographic screening for phase 3 trials of tanezumab in patients with osteoarthritis","volume":"2","author":"Guermazi","year":"2022","journal-title":"Osteoarthr Imaging"},{"key":"10.1016\/j.joca.2023.08.010_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ostima.2022.100009","article-title":"The 15th international workshop on osteoarthritis imaging; \u201cOpen Up: the multifaceted nature of OA imaging\u201d","volume":"2","author":"Oei","year":"2022","journal-title":"Osteoarthr Imaging"},{"key":"10.1016\/j.joca.2023.08.010_bib16","first-page":"1439","article-title":"Postoperative outcome of patients who underwent total joint replacement during the tanezumab phase 3 osteoarthritis development program: a 24-week observational study","volume":"38","author":"Mont","year":"2021","journal-title":"Surg Technol Int"},{"key":"10.1016\/j.joca.2023.08.010_bib17","first-page":"51","article-title":"Rapid destructive coxarthritis","volume":"22","author":"Lequesne","year":"1970","journal-title":"Rhumatologie"},{"key":"10.1016\/j.joca.2023.08.010_bib18","first-page":"3320","article-title":"Radiographic exclusionary findings during screening for three phase III trials of subcutaneous tanezumab in patients with moderate to severe hip or knee osteoarthritis","volume":"72","author":"Guermazi","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.joca.2023.08.010_bib19","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12891-020-03367-2","article-title":"Risk factors and the natural history of accelerated knee osteoarthritis: a narrative review","volume":"21","author":"Driban","year":"2020","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.joca.2023.08.010_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1067\/j.cpradiol.2016.02.012","article-title":"Disappearing acts: the many causes of rapidly destructive arthritis","volume":"46","author":"Porrino","year":"2017","journal-title":"Curr Probl Diagn Radiol"},{"key":"10.1016\/j.joca.2023.08.010_bib21","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/acr.20614","article-title":"Identifying common trajectories of joint space narrowing over two years in knee osteoarthritis","volume":"63","author":"Bartlett","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.joca.2023.08.010_bib22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/1529-0131(200005)43:5<988::AID-ANR5>3.0.CO;2-X","article-title":"Quantification of progressive joint space narrowing in osteoarthritis of the hip: longitudinal analysis of the contralateral hip after total hip arthroplasty","volume":"43","author":"Goker","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2023.08.010_bib23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.20149","article-title":"One-year change in radiographic joint space width in patients with unilateral joint space narrowing: data from the Osteoarthritis Initiative","volume":"62","author":"Benichou","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.joca.2023.08.010_bib24","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.joca.2007.12.004","article-title":"Joint space narrowing and Kellgren-Lawrence progression in knee osteoarthritis: an analytic literature synthesis","volume":"16","author":"Emrani","year":"2008","journal-title":"Osteoarthr Cartilage"},{"key":"10.1016\/j.joca.2023.08.010_bib25","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00256-019-03189-x","article-title":"Are patients more likely to have hip osteoarthritis progression and femoral head collapse after hip steroid\/anesthetic injections? A retrospective observational study","volume":"48","author":"Simeone","year":"2019","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.joca.2023.08.010_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1148\/radiol.2020200771","article-title":"Intra-articular corticosteroid injections for the treatment of hip and knee osteoarthritis-related pain: considerations and controversies with a focus on imaging\u2014Radiology Scientific Expert Panel","volume":"297","author":"Guermazi","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.joca.2023.08.010_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/17453677908989752","article-title":"Indomethacin treatment in osteoarthritis of the hip joint. Does the treatment interfere with the natural course of the disease?","volume":"50","author":"R\u00f8nningen","year":"1979","journal-title":"Acta Orthop Scand"},{"key":"10.1016\/j.joca.2023.08.010_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0140-6736(85)90058-3","article-title":"Acetabular bone destruction related to non-steroidal anti-inflammatory drugs","volume":"2","author":"Newman","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.joca.2023.08.010_bib29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ard.45.4.272","article-title":"A reappraisal of \u2018analgesic hip\u2019","volume":"45","author":"Doherty","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2023.08.010_bib30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/acr2.11058","article-title":"Adults with incident accelerated knee osteoarthritis are more likely to use pharmacological treatment options and receive arthroscopic knee surgery: data from the Osteoarthritis Initiative","volume":"1","author":"Davis","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.joca.2023.08.010_bib31","unstructured":"Pfizer. Pfizer reports third-quarter 2021 results; 2021. URL: \u3008https:\/\/investors.pfizer.com\/investor-news\/press-release-details\/2021\/PFIZER-REPORTS-THIRD-QUARTER-2021-RESULTS\/default.aspx\u3009. [Accessed November 23, 2021]."},{"key":"10.1016\/j.joca.2023.08.010_bib32","unstructured":"Eli Lilly and Company. Lilly reports robust third-quarter 2021 financial results as pipeline success strengthens future growth potential; 2021. URL: \u3008https:\/\/investor.lilly.com\/static-files\/a0b77c52-a997\u201341c1\u20139534-5f465903a0b4\u3009. [Accessed November 23, 2021]."}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458423008944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458423008944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T04:01:39Z","timestamp":1761019299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458423008944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1063458423008944"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2023.08.010","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2023.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.","name":"copyright","label":"Copyright"}]}}